Tramadol: keep calm and carry on

Paediatric Anaesthesia

Volumn 27, Issue 8, 2017, Pages 785-788

  Anderson, Brian J ^a   Thomas, Jane ^b   Ottaway, Kaye ^a   Chalkiadis, George A ^c  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b STARSHIP CHILDREN S HOSPITAL   (New Zealand)

^c ROYAL CHILDREN'S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CODEINE; CYTOCHROME P450 2D6; HYDROMORPHONE; NOROXYMORPHONE; OPIATE; OXYCODONE; PETHIDINE; TRAMADOL; UNCLASSIFIED DRUG; NARCOTIC ANALGESIC AGENT;

ADENOTONSILLECTOMY; AGE; ANALGESIC ACTIVITY; BREAST FEEDING; BREATHING DISORDER; CAUSE OF DEATH; CONSTIPATION; CYP2D6 GENE; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG INFORMATION; DRUG METABOLISM; DRUG OVERDOSE; DRUG RESPONSE; DRUG SAFETY; DRUG SENSITIVITY; EDITORIAL; FATIGUE; FEVER; FOOD AND DRUG ADMINISTRATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN; IATROGENIC DISEASE; LUNG DISEASE; NAUSEA; PEDIATRIC ANESTHESIA; POSTOPERATIVE PAIN; PRACTICE GUIDELINE; PRIORITY JOURNAL; RESPIRATION DEPRESSION; SEIZURE; SIDE EFFECT; SLEEP DISORDERED BREATHING; SOMNOLENCE; UNITED STATES; VOMITING; CHEMICALLY INDUCED; METABOLISM; MORTALITY; RESPIRATORY FAILURE;

ANALGESICS, OPIOID; CODEINE; CYTOCHROME P-450 CYP2D6; HUMANS; RESPIRATORY INSUFFICIENCY; TRAMADOL; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 85021873046     PISSN: 11555645     EISSN: 14609592     Source Type: Journal    
DOI: 10.1111/pan.13190     Document Type: Editorial

References (33)

1. Grond S, Sablotzki A. Clinical pharmacology of tramadol. Clin Pharmacokinet. 2004;43:879-923.
2. Poulsen L, Arendt-Nielsen L, Brosen K, et al. The hypoalgesic effect of tramadol in relation to CYP2D6. Clin Pharmacol Ther. 1996;60:636-644.
3. Tobias JD, Green TP, Cote CJ, et al. Codeine: Time to Say “No”. Pediatrics. 2016;138.
4. Morell RC. FDA group urges sux label reduced to “warning”. J Clin Monit. 1995;11:141-143.
5. Goudsouzian NG. Recent changes in the package insert for succinylcholine chloride: should this drug be contraindicated for routine use in children and adolescents? (Summary of the discussions of the anesthetic and life support drug advisory meeting of the Food and Drug Administration, FDA building, Rockville, MD, June 9, 1994). Anesth Analg. 1995;80:207-208.
6. Faine B, Hogrefe C. News flash: Old Mother Hubbard reports the cupboard is bare…time for the FDA to let droperidol out of the (black) box. Annals Pharmacother. 2012;46:1259-1261.
7. Matlock A, Allan N, Wills B, et al. A continuing black hole? The FDA boxed warning: an appeal to improve its clinical utility Clin Toxicol (Phila). 2011;49:443-447.
8. Hansen TG. Use of anaesthetics in young children: Consensus statement of the European Society of Anaesthesiology, the European Society for Paediatric Anaesthesiology, the European Association of Cardiothoracic Anaesthesiology and the European Safe Tots Anaesthesia Research Initiative. Eur J Anaesthesiol. 2017;34:327-328.
9. Enggaard TP, Poulsen L, Arendt-Nielsen L, et al. The analgesic effect of tramadol after intravenous injection in healthy volunteers in relation to CYP2D6. Anesth Analg. 2006;102:146-150.
10. Allegaert K, Anderson BJ, Verbesselt R, et al. Tramadol disposition in the very young: an attempt to assess in vivo cytochrome P-450 2D6 activity. Br J Anaesth. 2005;95:231-239.
11. Allegaert K, Holford N, Anderson BJ, et al. Tramadol and o-desmethyl tramadol clearance maturation and disposition in humans: a pooled pharmacokinetic study. Clin Pharmacokinet. 2015;54:167-178.
12. Allegaert K, Rochette A, Veyckemans F. Developmental pharmacology of tramadol during infancy: ontogeny, pharmacogenetics and elimination clearance. Paediatr Anaesth. 2011;21:266-273.
13. Allegaert K, van den Anker JN, de Hoon JN, et al. Covariates of tramadol disposition in the first months of life. Br J Anaesth. 2008;100:525-532.
14. Garrido MJ, Habre W, Rombout F, et al. Population pharmacokinetic/pharmacodynamic modelling of the analgesic effects of tramadol in pediatrics. Pharm Res. 2006;23:2014-2023.
15. Stauble ME, Moore AW, Langman LJ, et al. Hydrocodone in postoperative personalized pain management: pro-drug or drug? Clin Chim Acta. 2014;429:26-29.
16. Yee MM, Josephson C, Hill CE, et al. Cytochrome P450 2D6 polymorphisms and predicted opioid metabolism in African American children with sickle cell disease. J Pediatr Hematol Oncol. 2013;35:e301-e305.
17. Balyan R, Mecoli M, Venkatasubramanian R, et al. CYP2D6 pharmacogenetic and oxycodone pharmacokinetic association study in pediatric surgical patients. Pharmacogenomics. 2017;18:337-348.
18. Samer CF, Daali Y, Wagner M, et al. Genetic polymorphisms and drug interactions modulating CYP2D6 and CYP3A activities have a major effect on oxycodone analgesic efficacy and safety. Br J Pharmacol. 2010;160:919-930.
19. Lam J, Kelly L, Ciszkowski C, et al. Central nervous system depression of neonates breastfed by mothers receiving oxycodone for postpartum analgesia. J Pediatr. 2012;160:e32.
20. Olkkola KT, Hamunen K, Seppala T, et al. Pharmacokinetics and ventilatory effects of intravenous oxycodone in postoperative children. Br J Clin Pharmacol. 1994;38:71-76.
21. Jannetto PJ, Wong SH, Gock SB, et al. Pharmacogenomics as molecular autopsy for postmortem forensic toxicology: genotyping cytochrome P450 2D6 for oxycodone cases. J Anal Toxicol. 2002;26:438-447.
22. Hassanian-Moghaddam H, Farnaghi F, Rahimi M. Tramadol overdose and apnea in hospitalized children, a review of 20 cases. Res Pharm Sci. 2015;10:544-552.
23. Stassinos GL, Gonzales L, Klein-Schwartz W. Characterizing the toxicity and dose-effect profile of tramadol ingestions in children. Pediatr Emerg Care 2017. https://doi.org/10.1097/PEC.0000000000001084.
24. Spiller HA, Gorman SE, Villalobos D, et al. Prospective multicenter evaluation of tramadol exposure. J Toxicol Clin Toxicol. 1997;35:361-364.
25. Orliaguet G, Hamza J, Couloigner V, et al. A case of respiratory depression in a child with ultrarapid CYP2D6 metabolism after tramadol. Pediatrics. 2015;135:e753-e755.
26. Waters KA, McBrien F, Stewart P, et al. Effects of OSA, inhalational anesthesia, and fentanyl on the airway and ventilation of children. J Appl Physiol (1985). 2002;92:1987-1994.
27. Gammal RS, Crews KR, Haidar CE, et al. Pharmacogenetics for safe codeine use in sickle cell disease. Pediatrics. 2016;138. pii: e20153479. https://doi/org/10.1542/peds.2015-3479.
28. Dawes JM, Cooke EM, Hannam JA, et al. Oral morphine dosing predictions based on single dose in healthy children undergoing surgery. Paediatr Anaesth. 2016;27:28-36.
29. Brown SC, Stinson J. Treatment of pediatric chronic pain with tramadol hydrochloride: siblings with Ehlers-Danlos syndrome - Hypermobility type. Pain Res Manag. 2004;9:209-211.
30. Langford RM, Knaggs R, Farquhar-Smith P, et al. Is tapentadol different from classical opioids? A review of the evidence. Br J Pain. 2016;10:217-221.
31. Bosenberg AT, Ratcliffe S. The respiratory effects of tramadol in children under halothane anesthesia. Anaesthesia. 1998;53:960-964.
32. Tarkkila P, Tuominen M, Lindgren L. Comparison of respiratory effects of tramadol and oxycodone. J Clin Anesth. 1997;9:582-585.
33. Tarkkila P, Tuominen M, Lindgren L. Comparison of respiratory effects of tramadol and pethidine. Eur J Anaesthesiol. 1998;15:64-68.